Chemically modified heparins inhibit fibrinogen-bridged indirect adhesion between tumor cells and platelets

Zheng,Sheng; Liu,Yan; Jiao,Yang; Wei,Min; Zeng,Xianlu

doi:10.3892/ol.2011.510

Chemically modified heparins inhibit fibrinogen-bridged indirect adhesion between tumor cells and platelets

Authors:
- Sheng Zheng
- Yan Liu
- Yang Jiao
- Min Wei
- Xianlu Zeng
View Affiliations

Affiliations: Institute of Genetics and Cytology, School of Life Science, Northeast Normal University, 130024 Changchun, P.R. China
Published online on: December 2, 2011 https://doi.org/10.3892/ol.2011.510
Pages: 497-502

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The interaction between platelets and tumor cells is critical for the hematogenous metastasis of tumor cells. We recently reported that fibrinogen was capable of bridging and enhancing the interaction of platelets and tumor cells under conditions of physical shear force. In the present study, we aimed to detect the effects of 8 chemically modified heparins on the binding of fibrinogen to platelets or tumor cells using flow cytometry assays, as well as the fibrinogen-bridged adhesion of platelets and tumor cells using flow chamber assays. The results showed that fibrinogen binds to platelets and tumor cells in a β3 integrin‑dependent manner and bridges the adhesion between platelets and tumor cells. Heparin and certain chemically modified heparins, including borohydride-reduced (RO)-, carboxyl-reduced (CR)- and 2-O, 3-O-desulfated (2/3ODS)-heparins, inhibited the β3 integrin-dependent adhesion of fibrinogen to platelets or tumor cells, and consequently blocked the fibrinogen-bridged indirect adhesion of platelets to tumor cells. These data indicate that chemically modified heparins should be potential inhibitors for the fibrinogen-bridged indirect adhesion of platelets and tumor cells, which provides a novel explanation of the anti-adhesion property of heparin and proposes a new anti-metastatic target for cancer treatment.

View Figures

View References

1	Weiler H: A platelet cloak for tumor cells. Blood. 105:5–6. 2005. View Article : Google Scholar
2	Nieswandt B, Hafner M, Echtenacher B and Männel DN: Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59:1295–1300. 1999.PubMed/NCBI
3	Montrucchio G, Sapino A, Bussolati B, Ghisolfi G, Rizea-Savu S, Silvestro L, Lupia E and Camussi G: Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol. 153:1589–1596. 1998. View Article : Google Scholar : PubMed/NCBI
4	Manegold PC, Hutter J, Pahernik SA, Messmer K and Dellian M: Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood. 101:1970–1976. 2003. View Article : Google Scholar : PubMed/NCBI
5	Trikha M and Nakada MT: Platelets and cancer: implications for antiangiogenic therapy. Semin Thromb Hemost. 28:39–44. 2002. View Article : Google Scholar : PubMed/NCBI
6	McCarty OJ, Mousa SA, Bray PF and Konstantopoulos K: Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood. 96:1789–1797. 2000.PubMed/NCBI
7	Ishai-Michaeli R, Eldor A and Vlodavsky I: Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul. 11:833–842. 1990.
8	Suzuki K, Aiura K, Ueda M and Kitajima M: The influence of platelets on the promotion of invasion by tumor cells and inhibition by anti-platelet agents. Pancreas. 29:132–140. 2004. View Article : Google Scholar : PubMed/NCBI
9	Jurasz P, Alonso-Escolano D and Radomski MW: Platelet-cancer interactions: mechanisms and pharmacology of tumour cell- induced platelet aggregation. Br J Pharmacol. 143:819–826. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ma YQ and Geng JG: Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow. J Immunol. 165:558–565. 2000. View Article : Google Scholar : PubMed/NCBI
11	Felding-Habermann B, Habermann R, Saldívar E and Ruggeri ZM: Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem. 271:5892–5900. 1996. View Article : Google Scholar : PubMed/NCBI
12	Karpatkin S, Pearlstein E, Ambrogio C and Coller BS: Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest. 81:1012–1019. 1988. View Article : Google Scholar : PubMed/NCBI
13	Cominetti MR, Martin AC, Ribeiro JU, Djaafri I, Fauvel-Lafève F, Crépin M and Selistre-de-Araujo HS: Inhibition of platelets and tumor cell adhesion by the disintegrin domain of human ADAM9 to collagen I under dynamic flow conditions. Biochimie. 91:1045–1052. 2009. View Article : Google Scholar : PubMed/NCBI
14	Li F, Yu G, Li S, Peng S and Fu J: Antimetastatic effect of integrin IIb/IIIa inhibitors on salivary adenoid cystic carcinoma. Chin J Cancer Res. 13:198–201. 2010. View Article : Google Scholar
15	Varki NM and Varki A: Heparin inhibition of selectin-mediated interactions during the hemorrhagic phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost. 28:53–66. 2002. View Article : Google Scholar
16	Sobel M, Fish WR, Toma N, Luo S, Bird K, Mori K, Kusumoto S, Blystone SD and Suda Y: Heparin modulates integrin function in human platelets. J Vasc Surg. 33:587–594. 2001. View Article : Google Scholar : PubMed/NCBI
17	Wei M, Tai G, Gao Y, Li N, Huang B, Zhou Y, Hao S and Zeng X: Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J Biol Chem. 279:29202–29210. 2004. View Article : Google Scholar : PubMed/NCBI
18	Gao Y, Wei M, Zheng S, Ba X, Hao S and Zeng X: Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to P-selectin. J Cancer Res Clin Oncol. 132:257–264. 2006. View Article : Google Scholar : PubMed/NCBI
19	Zhang C, Liu Y, Gao Y, Shen J, Zheng S, Wei M and Zeng X: Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo. Int J Cancer. 125:2058–2065. 2009. View Article : Google Scholar : PubMed/NCBI
20	Zheng S, Shen S, Jiao Y, Liu Y, Zhang C, Wei M, Hao S and Zeng X: Platelets and fibrinogen facilitate each other in protecting tumor cells from NK cytotoxicity. Cancer Sci. 100:859–865. 2009. View Article : Google Scholar : PubMed/NCBI
21	Vestweber D and Blanks JE: Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev. 79:181–213. 1999.PubMed/NCBI
22	Diamond MS, Alon R, Parkos CA, Quinn MT and Springer TA: Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol. 130:1473–1482. 1995. View Article : Google Scholar : PubMed/NCBI
23	Gunji Y, Lewis J and Gorelik E: Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine- activated killer cells. Blood Coagul Fibrinolysis. 6:663–672. 1990.PubMed/NCBI
24	Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M and Degen JL: Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 105:178–185. 2005. View Article : Google Scholar : PubMed/NCBI
25	Leung L and Nachman R: Molecular mechanisms of platelet aggregation. Annu Rev Med. 37:179–186. 1986. View Article : Google Scholar